Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Roots Analysis | PRODUCT CODE: 1164938

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 1164938

Patient Recruitment Services & Patient Retention Services Market by Therapeutic Area, Patient Recruitment Step, Trial Phase & Key Geographies: Industry Analysis & Global Forecasts, 2022-2035

PUBLISHED:
PAGES: 350 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4799
PDF (One-Location Site License)
USD 6999
PDF (Department License)
USD 10599
PDF (Enterprise License)
USD 17999

Add to Cart

INTRODUCTION

Clinical trials form an integral part of the overall drug development process, enabling the necessary evaluation of the safety and efficacy of a drug candidate. As these trials are prone to delays, and can even fail altogether, they impose an immense financial pressure on sponsors. Studies suggest that around 40% of the total investment made for the development of a drug candidate is dedicated to clinical trials. However, the conduct of such trials is often fraught with challenges, including scientific and operational complexity, concerns associated with recruitment and retention of suitable patients, issues related to data handling and increasingly stringent regulatory guidelines. Further, owing to the inherent complexity of the overall process and involvement of several different stakeholders, these trials are prone to delays. It is worth mentioning that around 80% of the clinical trials are delayed due to insufficient patient recruitment. Further, retaining patients is also a major concern in pharmaceutical research and development; 15% to 40% of the enrolled patients drop out before the studies are completed, significantly impacting product approvals / launch timelines. Therefore, patient outreach, recruitment and retention strategies have evolved significantly, especially with the availability of a variety of digital data generation, management and marketing solutions. In fact, a number of modern technology-enabled offerings are now available to support various aspects of clinical research and patient recruitment.

Q1. What is the current market landscape of the patient recruitment and retention services market?

Amongst several known challenges, patient recruitment is considered to be one of the rate limiting steps when it comes to getting drugs to the market. Presently, more than 155 companies have the required capabilities to offer patient recruitment and retention services across different geographical locations. Such service providers employ a variety of outreach methods and, over time, have attained a vital role in the successful conduct of clinical research. Further, several contract service providers are entering into strategic alliances in order to enhance their respective capabilities and offer an expanded portfolio of services to their clients.

Q2. How has outsourcing evolved in the patient recruitment and retention domain?

Several small and mid-sized players do not have dedicated patient enrolment teams and lack the necessary capabilities / expertise to successfully recruit desired number of patients in clinical trials. In some cases, the clinical studies are too large or geographically broad to be managed by internal staff. Further, the stringent ethical and regulatory guidelines associated with patient enrollment in trials impose a significant burden on drug developers. As a result, outsourcing has become a popular operating model with regards to patient recruitment and retention; several specialty service providers, with expertise and experience in this domain, are driving the growth of this upcoming segment of the healthcare market. The advantages of engaging contract service providers are numerous and enable sponsors to meet their clinical research timelines and thereby, launch respective offerings as planned.

Q3. What are the recent developments and expected trends in the patient recruitment and retention domain?

Over the past decade, the patient recruitment and retention industry has witnessed tremendous increase in the use of social media platforms, including Facebook, Instagram, Pinterest, LinkedIn and Twitter, and mobile applications for engaging and recruiting patients in clinical studies; these approaches are cost-effective and can be used to connect with diverse and hard-to-reach patient populations. In pursuit of capability and competence improvements, several service providers have also begun adopting and implementing modern technical strategies, such as Electronic Health Records (EHRs) and Real-World Evidence (RWE) for patient enrolment; these novel methods tend to be more efficient and yield a narrow pool of potentially eligible participants for targeted mailings.

Q4. What are the key challenges faced by patient recruitment and retention service providers?

The primary challenge faced by patient recruitment and retention service providers is the lack of awareness amongst individuals regarding the clinical studies and the benefits offered to study participants. Further, pharmaceutical companies do not allocate adequate budget for carrying out the patient enrolment process. Specifically for clinical trials evaluating orphan drugs and personalized therapies, finding the specialized pool of eligible patients is a burdensome and costly task. Other challenges in this domain include fear of individuals about the adverse events associated with clinical trials, lack of communication between study participants and researchers due to language barrier, and large geographical distance between the patient's residence and study site, which affect the participation and retention of patients in research studies.

Q5. What are the key value drivers in the patient recruitment and retention service market?

Owing to rise in the number of clinical trials that seek to enroll millions of patients, and complexities associated with patient accrual, drug developers are likely to outsource the patient recruitment and retention process to service providers. Moreover, we believe that increase in clinical development activity in emerging markets, availability of one-stop patient recruitment service providers, and stringent regulations related to patient enrollment are likely to provide further impetus to the patient recruitment services market.

Q6. What is the current market scenario and likely growth associated with patient recruitment services domain?

The patient recruitment services market is anticipated to grow at a steady pace in the coming years. Owing to the need for large and diverse patient populations, phase III trials are anticipated to be responsible for the maximum share of revenues within this domain. Currently, in terms of therapeutic area, the market is captured by patient recruitment projects for trials evaluating drugs intended for the treatment of cardiovascular disorders. However, this trend is likely to change in the foreseen future with the rising clinical trials focusing on therapeutics targeting oncological disorders. Specifically, in terms of geography, the patient recruitment services market in Asia Pacific is likely to grow at a relatively faster pace in the long term.

SCOPE OF THE REPORT

The "Patient Recruitment and Retention Services Market (3rd Edition), 2022-2035: Distribution by Patient Recruitment Step (Pre-screening and Screening), Trial Phase (Phase I, Phase II, Phase III and Phase IV) Therapeutic Area (Cardiovascular Diseases, Oncological Disorders, Infectious Diseases, CNS Disorders, Respiratory Disorders, Hematological Disorders, Dermatological Disorders, Ophthalmic Disorders and Others) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World)" report features an extensive study of the current market landscape and future potential of the patient recruitment and retention services market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report includes:

  • A general overview of the clinical trials, featuring information on the different phases of clinical trials and their importance. The chapter also lays emphasis on patient recruitment process, its associated challenges and the different strategies used to enhance patient enrolment in clinical research studies. It also presents information on the affiliated ethical considerations and outsourcing activity in this domain. Further, it features an elaborate discussion on the various patient recruitment associated services offered by contract service providers as well as the patient retention strategies employed to prevent drop-out of enrolled individuals from clinical trials.
  • A brief information on the various types of patient outreach methods used by contract service providers in this domain, to identify and enroll patients in clinical trials. Further, the chapter highlights the various advantages and limitations of these outreach methods.
  • A detailed assessment of the overall landscape of companies offering patient recruitment and retention services, along with the information on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, patient recruitment and retention services offered, patient outreach methods (social media outreach, traditional media outreach, directly approaching individual patients, leveraging proprietary patient databases, exploiting patient communities and advocacy groups, engaging local enrolment specialists, using digital advertising solutions, organizing large scale events / campaigns and exploiting real world data sources), number of patient outreach methods (less than 3 methods, 3 to 6 methods and more than 6 methods), patient recruitment associated service(s) offered (pre-screening potential study participants, study feasibility / protocol development, site identification and selection, project management, site management, IRB/EC submission, core CRO services, clinical monitoring, web development solutions, clinical trial data management, real-time enquiry / information support and investigator grant management), number of patient recruitment associated service(s) offered (less than 3 associated services, 3 to 6 associated services and more than 6 associated services), patient retention method(s) used (dedicated patient engagement solutions, offering study-branded amenities / education materials and offering transportation (to site) support), number of patient retention method(s) used (less than 2 methods, 2 to 5 methods and more than 5 methods), geographical reach (North America, Europe, Asia-Pacific and Rest of the World), therapeutic expertise (respiratory disorders, gastrointestinal disorders, healthy volunteers, cardiovascular disorders, central nervous system and mental health disorders, metabolic disorders, dermatological disorders, oncological disorders, musculoskeletal disorders, infectious diseases, autoimmune disorders, ophthalmic disorders, medical devices, rare diseases / personalized therapies and others). The chapter also covers details on the payment model, patient recruitment platforms / technologies used and the various certifications / accreditations awarded by regulatory bodies.
  • A detailed competitiveness analysis of patient recruitment and retention service providers, taking into consideration supplier strength (based on their experience in this field) and service strength (based on number of patient outreach methods, number of patient recruitment associated service(s) offered, number of patient retention method(s) used, geographical reach and therapeutic expertise).
  • Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) offering patient recruitment and retention services, across North America, Europe, and Asia-Pacific and Rest of the World. Each profile features a brief overview of the company, along with details related to its patient recruitment and retention service portfolio, recent developments and an informed future outlook.
  • An insightful analysis of the recent collaborations within the patient recruitment and retention industry, based on several relevant parameters, such as year of partnership, type of partnership (acquisitions, joint ventures, mergers, patient recruitment agreements, service alliances, technology development agreements, technology licensing agreements and others), focus area (clinical trial management, patient recruitment and patient retention), therapeutic area (autoimmune disorders, cardiovascular disorders, CNS disorders, dermatological disorders, metabolic disorders, oncological disorders, pain, rare diseases, respiratory disorders, and others), most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2013-2022.
  • A review of the emerging trends in the patient recruitment industry, including the use of social media, mobile technologies, electronic health records (EHR), real-world evidence (RWE) and artificial intelligence, to overcome the challenges associated with patient enrolment and retention.
  • A detailed discussion on the key growth opportunities (such as rise in the number of clinical trials, development of personalized medicines / orphan drugs, growing opportunities in emerging markets, increasing preference for one-stop solutions, stringent regulations related to patient enrollment and technological advancements in clinical trial conduct) in the field of patient recruitment and retention that are likely to impact the evolution of the market over the coming years.
  • A case study on regulatory landscape of patient recruitment, highlighting the regulatory process involved in patient enrollment, along with the information on regulatory guidelines, regulatory framework for patient recruitment, ethics committees in different countries and documents reviewed by the ethics committees.
  • A brief overview of patient recruitment in clinical trials focused on personalized medicines and rare diseases, highlighting the key challenges in patient enrollment, specialized patient outreach methods being used to recruit and the key players engaged in this field.
  • A detailed analysis of the annual demand for study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.
  • A detailed assessment on the impact of the COVID-19 pandemic on the patient recruitment and retention services market. In addition, it features various strategies that different companies adopted in order to mitigate the challenges associated with patient recruitment faced during the global crisis.

One of the key objectives of the report was to evaluate the current opportunity and the future growth potential of the patient recruitment and retention services market over the coming years. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. The report also features a likely distribution of the current and forecasted opportunity across important parameters, such as [A] patient recruitment steps (pre-screening and screening), [B] trial phase (phase I, phase II, phase III and phase IV), [C] therapeutic area (cardiovascular disorders, oncological disorders, infectious diseases, CNS disorders, respiratory disorders, haematological disorders, metabolic disorders, dermatological disorders, ophthalmic disorders and others) and [D] key geographies (North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America and Rest of the World).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following individuals:

  • Susan Fitzpatrick-Napier (Founder and Director, TrialWire)
  • Kate Shaw (Chief Executive Officer and Founder) and Marco Lassandro (Marketing and Communications Manager, Innovative Trials)
  • Simon Klaasen (Co-founder and Managing Director, Link2Trials)
  • Stefan Mayer-Eggersmann (Chief Commercial Officer, Clariness)
  • Ken Shore (Chief Commercial Officer, Continuum Clinical)
  • Hagit Nof (Chief Operation Officer and Business Development Officer, nRollmed)
  • Paul Ivsin (Ex-Managing Director, Seeker Health)
  • Kasturi Lakhe (Inside Sales Specialist, EVERSANA)

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES

Chapter 2 is an executive summary of the insights captured in our report. It offers a high-level view of the current state of the patient recruitment and retention services market and its likely evolution in the short term, mid-term and long term.

Chapter 3 provides a general overview of the clinical trials, featuring information on the different phases of clinical trials and their importance. The chapter also lays emphasis on patient recruitment process, its associated challenges and the different strategies used to enhance patient enrolment in clinical research studies. It also presents information on the affiliated ethical considerations and outsourcing activity in this domain. Further, it features an elaborate discussion on the various patient recruitment associated services offered by contract service providers as well as the patient retention strategies employed to prevent drop-out of enrolled individuals from clinical trials.

Chapter 4 provides a brief information on the various types of patient outreach methods used by contract service providers in this domain, to identify and enroll patients in clinical trials. Further, the chapter highlights the various advantages and limitations of these outreach methods.

Chapter 5 features a detailed review of the overall market landscape of patient recruitment and retention services providers, along with the information on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, patient recruitment and retention services offered, patient outreach methods (social media outreach, traditional media outreach, directly approaching individual patients, leveraging proprietary patient databases, exploiting patient communities and advocacy groups, engaging local enrolment specialists, using digital advertising solutions, organizing large scale events / campaigns and exploiting real world data sources), number of patient outreach methods (less than 3 methods, 3 to 6 methods and more than 6 methods), patient recruitment associated service(s) offered (pre-screening potential study participants, study feasibility / protocol development, site identification and selection, project management, site management, IRB/EC submission, core CRO services, clinical monitoring, web development solutions, clinical trial data management, real-time enquiry / information support and investigator grant management), number of patient recruitment associated service(s) offered (less than 3 associated services, 3 to 6 associated services and more than 6 associated services), patient retention method(s) used (dedicated patient engagement solutions, offering study-branded amenities / education materials and offering transportation (to site) support), number of patient retention method(s) used (less than 2 methods, 2 to 5 methods and more than 5 methods), geographical reach (North America, Europe, Asia-Pacific and Rest of the World), therapeutic expertise (respiratory disorders, gastrointestinal disorders, healthy volunteers, cardiovascular disorders, central nervous system and mental health disorders, metabolic disorders, dermatological disorders, oncological disorders, musculoskeletal disorders, infectious diseases, autoimmune disorders, ophthalmic disorders, medical devices, rare diseases / personalized therapies and others). The chapter also covers details on the payment model, patient recruitment platforms / technologies used, and the various certifications / accreditations awarded by regulatory bodies.

Chapter 6 presents insightful company competitiveness analysis of patient recruitment and retention service providers. The companies are further segmented based on their company size, into three categories, namely small companies, mid-sized companies, and large and very large companies. The analysis compares the contract service providers on the basis of various parameters, such as number of patient outreach methods, number of patient recruitment associated service(s) offered, number of patient retention service(s) used, geographical reach and therapeutic expertise.

Chapter 7 features detailed profiles of the prominent companies that offer patient recruitment and retention services in North America. Each company profile features a brief overview of the company (including information on their headquarters, year of establishment, number of employees and key executives), details related to patient recruitment and retention service portfolio, recent developments and an informed future outlook.

Chapter 8 features detailed profiles of the prominent companies that offer patient recruitment and retention services in Europe. Each company profile features a brief overview of the company (including information on their headquarters, year of establishment, number of employees and key executives), details related to patient recruitment and retention service portfolio, recent developments and an informed future outlook.

Chapter 9 features detailed profiles of the prominent companies that offer patient recruitment and retention services in Asia-Pacific and Rest of the World. Each company profile features a brief overview of the company (including information on their headquarters, year of establishment, number of employees and key executives), details related to patient recruitment and retention service portfolio, recent developments and an informed future outlook.

Chapter 10 features an elaborate analysis of the several recent collaborations within the patient recruitment and retention domain, in the period 2013 - 2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership (acquisitions, joint ventures, mergers, patient recruitment agreements, service alliances, technology development agreements, technology licensing agreements and others), focus area (clinical trial management, patient recruitment and patient retention), therapeutic area (autoimmune disorders, cardiovascular disorders, CNS disorders, dermatological disorders, metabolic disorders, oncological disorders, pain, rare diseases, respiratory disorders, and others), most active player(s) (in terms of number of deals inked) and regional distribution of partnership activity.

Chapter 11 provides a detailed review of emerging trends in the industry, including the use of social media, mobile technologies, EHR, RWE and artificial intelligence, to overcome the challenges associated with patient enrolment and retention.

Chapter 12 features a detailed discussion on the key growth opportunities and upcoming trends (such as rise in the number of clinical trials, development of personalized medicine / orphan drugs, growing opportunities in emerging markets, increasing preference for one-stop solutions, stringent regulations related to patient enrollment and technological advancements in clinical trial conduct) in the field of patient recruitment and retention that are likely to impact the evolution of the market over the coming years.

Chapter 13 present a case study on regulatory landscape of patient recruitment, highlighting the regulatory process involved in patient enrollment, along with the information on regulatory guidelines, regulatory framework for patient recruitment, ethics committees in different countries and documents reviewed by the ethics committees.

Chapter 14 features a brief overview of patient recruitment in clinical trials focused on personalized medicines and rare diseases, highlighting the key challenges in patient enrollment, specialized patient outreach methods being utilized to recruit and the key players engaged in this field.

Chapter 15 provides a detailed analysis of the annual demand for study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.

Chapter 16 features a comprehensive market forecast analysis, highlighting the likely growth of the patient recruitment and retention services market, till 2035. In order to provide details on the future outlook, our projections have been segmented on the basis of [A] patient recruitment steps (pre-screening and screening), [B] trial phase (phase I, phase II, phase III and phase IV), [C] therapeutic area (cardiovascular disorders, oncological disorders, infectious diseases, CNS disorders, respiratory disorders, haematological disorders, metabolic disorders, dermatological disorders, ophthalmic disorders and others) and [D] key geographies (North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America and Rest of the World). It is worth mentioning that we adopted a mixture of top-down approach for this analysis, backing our claims with relevant datapoints and credible inputs from primary research.

Chapter 17 provides a detailed assessment on the impact of the COVID-19 pandemic on the patient recruitment and retention services market. In addition, it features various strategies that different companies have adopted in order to mitigate the challenges associated with patient recruitment faced during the global crisis.

Chapter 18 summarizes the overall report. The chapter provides the key takeaways from the report and expresses our independent opinion of the patient recruitment and retention services market, based on the research and analysis described in the previous chapters.

Chapter 19 is a collection of interview transcripts of the discussions held with key stakeholders in this domain. In this chapter, we have presented the details of interview held with Susan Fitzpatrick-Napier (Founder and Director, TrialWire), Kate Shaw and Marco Lassandro (Chief Executive Officer and Founder, and Marketing and Communications Manager, Innovative Trials), Simon Klaasen (Co-founder and Managing Director, Link2Trials), Stefan Mayer-Eggersmann (Chief Commercial Officer, Clariness), Ken Shore (Chief Commercial Officer, Continuum Clinical), Hagit Nof (Chief Operation Officer and Business Development Officer, nRollmed), Paul Ivsin (Ex-Managing Director, Seeker Health) and Kasturi Lakhe (Inside Sales Specialist, EVERSANA).

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 21 is an appendix, which contains the list of companies and organizations mentioned in the report.

Product Code: RA100391

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Clinical Trials
    • 3.2.1 Clinical Trial Phases
  • 3.3. Patient Recruitment in Clinical Trials
    • 3.3.1. Patient Recruitment Process
    • 3.3.2. Challenges Associated with Patient Recruitment
    • 3.3.3. Strategies to Improve Patient Recruitment
    • 3.3.4. Ethical Considerations
  • 3.4. Outsourcing Patient Recruitment
    • 3.4.1. Patient Recruitment-related Services
  • 3.5. Patient Retention
    • 3.5.1. Patient Retention-related Services
  • 3.6. Concluding Remarks

4. PATIENT OUTREACH METHODS

  • 4.1. Chapter Overview
  • 4.2. Patient Outreach Methods
    • 4.2.1. Traditional Patient Outreach Methods
      • 4.2.1.1. Physician Referrals
      • 4.2.1.2. Television
      • 4.2.1.3. Radio
      • 4.2.1.4. Print Media
      • 4.2.1.5. Direct Mail Campaign
      • 4.2.1.6. Cold Call / Call Centre
      • 4.2.1.7. Advantages and Limitations of Traditional Media
    • 4.2.2. Emerging Patient Outreach Methods
      • 4.2.2.1. Social Media
        • 4.2.2.1.1. Geo-Social Media
        • 4.2.2.1.2. Social Networking Websites
        • 4.2.2.1.3. Advantages and Limitations of Social Media
      • 4.2.2.2. Mobile / Software Applications
      • 4.2.2.3. Patient Networks
      • 4.2.2.4. Patient Advocacy Groups
      • 4.2.2.5. Electronic Medical Records (EMRs) / Electronic Health Records (EHRs) and Other Health Registries
      • 4.2.2.6. Search Engine Marketing / Artificial Intelligence-based Marketing
      • 4.2.2.7. Over-the-top (OTT) Media Platforms
      • 4.2.2.8. Indication Specific Events for Patients
    • 4.2.3. Best Practices / Recommendations for Patient Outreach

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Patient Recruitment and Retention Service Providers: Overall Market Landscape
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Location of Headquarters
    • 5.2.4. Analysis by Company Size and Location of Headquarters
    • 5.2.5. Analysis by Patient Recruitment and Retention Services Offered
    • 5.2.6. Analysis by Patient Outreach Methods
    • 5.2.7. Analysis by Patient Recruitment Associated Service(s) Offered
    • 5.2.8. Analysis by Patient Retention Method(s) Used
    • 5.2.9. Analysis by Geographical Reach
    • 5.2.10. Analysis by Therapeutic Expertise
    • 5.2.11. Information on Payment Model, Recruitment Technology / Platform, and Regulatory Approval / Certification / Compliance Status

6. COMPANY COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Assumptions and Key Parameters
  • 6.3. Methodology
  • 6.4. Patient Recruitment and Retention Service Providers: Company Competitiveness Analysis
    • 6.4.1. Competitiveness Analysis: Small Companies
    • 6.4.2. Competitiveness Analysis: Mid-Sized Companies
    • 6.4.3. Competitiveness Analysis: Large and Very Large Companies

7. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN NORTH AMERICA

  • 7.1. Chapter Overview
  • 7.2. BBK Worldwide (A Publicis Health Company)
    • 7.2.1. Company Overview
    • 7.2.2. Patient Recruitment and Retention Services Portfolio
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. Continuum Clinical
    • 7.3.1. Company Overview
    • 7.3.2. Patient Recruitment and Retention Services Portfolio
    • 7.3.3. Recent Developments and Future Outlook
  • 7.4. IQVIA
    • 7.4.1. Company Overview
    • 7.4.2. Patient Recruitment and Retention Services Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. United BioSource (UBC)
    • 7.5.1. Company Overview
    • 7.5.2. Patient Recruitment and Retention Services Portfolio
    • 7.5.3. Recent Developments and Future Outlook
  • 7.6. WCG ThreeWire
    • 7.6.1. Company Overview
    • 7.6.2. Patient Recruitment and Retention Services Portfolio
    • 7.6.3. Recent Developments and Future Outlook

8. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN EUROPE

  • 8.1. Chapter Overview
  • 8.2. Clariness
    • 8.2.1. Company Overview
    • 8.2.2. Patient Recruitment and Retention Services Portfolio
    • 8.2.3. Recent Developments and Future Outlook
  • 8.3. Ignite Data
    • 8.3.1. Company Overview
    • 8.3.2. Capsule Communications: Patient Recruitment and Retention Services Portfolio
    • 8.3.3. Recent Developments and Future Outlook
  • 8.4. Innovative Trials
    • 8.4.1. Company Overview
    • 8.4.2. Patient Recruitment and Retention Services Portfolio
    • 8.4.3. Recent Developments and Future Outlook
  • 8.5. One Research
    • 8.5.1. Company Overview
    • 8.5.2. Patient Recruitment and Retention Services Portfolio
    • 8.5.3. Recent Developments and Future Outlook
  • 8.6. Orphan Reach
    • 8.6.1. Company Overview
    • 8.6.2. Patient Recruitment and Retention Services Portfolio
    • 8.6.3. Recent Developments and Future Outlook

9. COMPANY PROFILES: PATIENT RECRUITMENT AND RETENTION SERVICES PROVIDERS IN ASIA-PACIFIC AND REST OF THE WORLD

  • 9.1. Chapter Overview
  • 9.2. 3H Medi Solution
    • 9.2.1. Company Overview
    • 9.2.2. Patient Recruitment and Retention Services Portfolio
    • 9.2.3. Recent Developments and Future Outlook
  • 9.3. Buzzreach
    • 9.3.1. Company Overview
    • 9.3.2. Patient Recruitment and Retention Services Portfolio
    • 9.3.3. Recent Developments and Future Outlook
  • 9.4. Current Medical Information Center (CMIC)
    • 9.4.1. Company Overview
    • 9.4.2. Patient Recruitment and Retention Services Portfolio
    • 9.4.3. Recent Developments and Future Outlook
  • 9.5. nRollmed
    • 9.5.1. Company Overview
    • 9.5.2. Patient Recruitment and Retention Services Portfolio
    • 9.5.3. Recent Developments and Future Outlook
  • 9.6. Trialfacts
    • 9.6.1. Company Overview
    • 9.6.2. Patient Recruitment and Retention Services Portfolio
    • 9.6.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Patient Recruitment and Retention Services: List of Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Year and Type of Partnership
    • 10.3.4. Analysis by Focus Area
    • 10.3.5. Analysis by Year of Partnership and Focus Area
    • 10.3.6. Analysis by Therapeutic Area
    • 10.3.7. Analysis by Type of Partner
    • 10.3.8. Most Active Players: Analysis by Number of Partnerships
    • 10.3.9. Analysis by Geography
      • 10.3.9.1. Intracontinental and Intercontinental Deals
      • 10.3.9.2. International and Local Deals

11. RECENT TRENDS IN PATIENT RECRUITMENT AND RETENTION

  • 11.1. Chapter Overview
    • 11.1.1. Campaigning on Social Media to Accelerate Patient Recruitment in Clinical Trials
    • 11.1.2. Adoption of Mobile Technologies for Patient Recruitment and Retention
    • 11.1.3. Use of EHR Data to Improve Patient Recruitment Rates
    • 11.1.4. Use of Other Real-World Data Sources to Overcome Patient Enrolment-related Challenges
    • 11.1.5. Use of Artificial Intelligence to Improve Patient Selection
    • 11.1.6. Increase in Adoption of the Virtual Trial Model During the COVID-19 Pandemic
    • 11.1.7. Growing Focus on Conducting Clinical Research in Emerging Markets

12. FUTURE GROWTH OPPORTUNITIES IN PATIENT RECRUITMENT

  • 12.1. Chapter Overview
  • 12.2. Continuous Rise in the Number of Global Clinical Trials
  • 12.3. Rise in Demand for Orphan Drugs and Personalized Medicine
  • 12.4. Increase in Offshoring Clinical Development Activity to Emerging Regions
  • 12.5. Availability of Service Providers Offering One-Stop-Solutions
  • 12.6. Stringent Regulations and Complex Study Protocols Prompting More Outsourcing
  • 12.7. Impact of the COVID-19 Pandemic on Clinical Research Activity
  • 12.8. Technological Advances in Clinical Trial Conduct

13. CASE STUDY: REGULATORY LANDSCAPE OF PATIENT RECRUITMENT

  • 13.1. Chapter Overview
  • 13.2. Regulatory Framework of Patient Recruitment
  • 13.3. Regulations Involved in Patient Recruitment
    • 13.3.1. ICH-GCP Guidelines
    • 13.3.2. Declaration of Helsinki
    • 13.3.3. General Data Privacy Regulation (GDPR)
    • 13.3.4. Health Insurance Portability and Accountability Act (HIPAA)

14. PATIENT RECRUITMENT IN TRIALS FOCUSED ON PERSONALIZED MEDICINES AND RARE DISEASES

  • 14.1. Chapter Overview
  • 14.2. Clinical Trials Focused on Personalized Medicines and Rare Diseases
    • 14.2.1. Key Challenges
    • 14.2.2. Specialized Patient Outreach Methods
    • 14.2.3. Key Players

15. ANALYSIS OF DEMAND FOR CLINICAL TRIAL PARTICIPANTS

  • 15.1. Chapter Overview
  • 15.2. Scope and Methodology
  • 15.3. Clinical Trial Analysis
    • 15.3.1. Analysis by Trial Registration Year and Enrolled Patient Population
    • 15.3.2. Analysis by Trial Phase
  • 15.4. Global Demand for Clinical Trial Participants
    • 15.4.1. Analysis by Enrolled Patient Population
    • 15.4.2. Analysis by Trial Phase
    • 15.4.3. Analysis by Therapeutic Area
    • 15.4.4. Analysis by Enrolled Patient Population and Geography

16. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Forecast Methodology and Key Assumptions
  • 16.3. Global Patient Recruitment Services Market, 2022-2035
  • 16.4. Patient Recruitment Services Market: Analysis by Patient Recruitment Steps, 2022-2035
  • 16.5. Patient Recruitment Services Market: Analysis by Trial Phase, 2022-2035
  • 16.6. Patient Recruitment Services Market: Analysis by Therapeutic Area, 2022-2035
  • 16.7. Patient Recruitment Services Market: Analysis by Geography, 2022-2035
    • 16.7.1. Patient Recruitment Services: Market Attractiveness Analysis by Country, 2022-2035
    • 16.7.2. Patient Recruitment Services Market in North America, 2022-2035
      • 16.7.2.1. Patient Recruitment Services Market in the US: Analysis by Trial Phase, 2022-2035
      • 16.7.2.2. Patient Recruitment Services Market in the US: Analysis by Therapeutic Area, 2022-2035
      • 16.7.2.3. Patient Recruitment Services Market in Canada: Analysis by Trial Phase, 2022-2035
      • 16.7.2.4. Patient Recruitment Services Market in Canada: Analysis by Therapeutic Area, 2022-2035
    • 16.7.3. Patient Recruitment Services Market in Europe, 2022-2035
      • 16.7.3.1. Patient Recruitment Services Market in Germany: Analysis by Trial Phase, 2022-2035
      • 16.7.3.2. Patient Recruitment Services Market in Germany: Analysis by Therapeutic Area, 2022-2035
      • 16.7.3.3. Patient Recruitment Services Market in France: Analysis by Trial Phase, 2022-2035
      • 16.7.3.4. Patient Recruitment Services Market in France: Analysis by Therapeutic Area, 2022-2035
      • 16.7.3.5. Patient Recruitment Services Market in the UK: Analysis by Trial Phase, 2022-2035
      • 16.7.3.6. Patient Recruitment Services Market in the UK: Analysis by Therapeutic Area, 2022-2035
      • 16.7.3.7. Patient Recruitment Services Market in Italy: Analysis by Trial Phase, 2022-2035
      • 16.7.3.8. Patient Recruitment Services Market in Italy: Analysis by Therapeutic Area, 2022-2035
      • 16.7.3.9. Patient Recruitment Services Market in Spain: Analysis by Trial Phase, 2022-2035
      • 16.7.3.10. Patient Recruitment Services Market in Spain: Analysis by Therapeutic Area, 2022-2035
      • 16.7.3.11. Patient Recruitment Services Market in Rest of Europe: Analysis by Trial Phase, 2022-2035
      • 16.7.3.12. Patient Recruitment Services Market in Rest of Europe: Analysis by Therapeutic Area, 2022-2035
    • 16.7.4. Patient Recruitment Services Market in Asia-Pacific, 2022-2035
      • 16.7.4.1. Patient Recruitment Services Market in Japan: Analysis by Trial Phase, 2022-2035
      • 16.7.4.2. Patient Recruitment Services Market in Japan: Analysis by Therapeutic Area, 2022-2035
      • 16.7.4.3. Patient Recruitment Services Market in South Korea: Analysis by Trial Phase, 2022-2035
      • 16.7.4.4. Patient Recruitment Services Market in South Korea: Analysis by Therapeutic Area, 2022-2035
      • 16.7.4.5. Patient Recruitment Services Market in Australia: Analysis by Trial Phase, 2022-2035
      • 16.7.4.6. Patient Recruitment Services Market in Australia: Analysis by Therapeutic Area, 2022-2035
      • 16.7.4.7. Patient Recruitment Services Market in China: Analysis by Trial Phase, 2022-2035
      • 16.7.4.8. Patient Recruitment Services Market in China: Analysis by Therapeutic Area, 2022-2035
      • 16.7.4.9. Patient Recruitment Services Market in India: Analysis by Trial Phase, 2022-2035
      • 16.7.4.10. Patient Recruitment Services Market in India: Analysis by Therapeutic Area, 2022-2035
    • 16.7.5 Patient Recruitment Services Market in Latin America, 2022-2035
      • 16.7.5.1. Patient Recruitment Services Market in Latin America: Analysis by Trial Phase, 2022-2035
      • 16.7.5.2. Patient Recruitment Services Market in Latin America: Analysis by Therapeutic Area, 2022-2035
    • 16.7.6. Patient Recruitment Services Market in Middle East and North Africa, 2022-2035
      • 16.7.6.1. Patient Recruitment Services Market in Middle East and North Africa: Analysis by Trial Phase, 2022-2035
      • 16.7.6.2. Patient Recruitment Services Market in Middle East and North Africa: Analysis by Therapeutic Area, 2022-2035
    • 16.7.7. Patient Recruitment Services Market in Rest of the World, 2022-2035
      • 16.7.7.1. Patient Recruitment Services Market in Rest of the World: Analysis by Trial Phase, 2022-2035
      • 16.7.7.2. Patient Recruitment Services Market in Rest of the World: Analysis by Therapeutic Area, 2022-2035

17. IMPACT OF THE COVID-19 PANDEMIC ON PATIENT RECRUITMENT SERVICES MARKET

  • 17.1. Chapter Overview
  • 17.2. Impact of COVID-19 Pandemic on Clinical Trials
    • 17.2.1. Impact on Opportunity Related to Patient Recruitment Services
    • 17.2.2. Initiatives Undertaken by Key Patient Recruitment and Retention Service Providers
      • 17.2.2.1. Trialspark
      • 17.2.2.2. BBK Worldwide
      • 17.2.2.3. Clariness
      • 17.2.2.4. Clinical Site Services (CSSi)
      • 17.2.2.5. IQVIA
  • 17.3. Key Strategies Adopted to Mitigate the Challenges Associated with Patient Recruitment and Retention

18. CONCLUDING REMARKS

19. EXECUTIVE INSIGHTS

  • 19.1. Chapter Overview
  • 19.2. TrialWire
    • 19.2.1. Company Snapshot
    • 19.2.2. Interview Transcript: Susan Fitzpatrick-Napier, Founder and Director
  • 19.3. Innovative Trials
    • 19.3.1. Company Snapshot
    • 19.3.2. Interview Transcript: Kate Shaw, Chief Executive Officer and Founder, and Marco Lassandro, Marketing and Communications Manager
  • 19.4. Link2Trials
    • 19.4.1. Company Snapshot
    • 19.4.2. Interview Transcript: Simon Klaasen, Co-Founder and Managing Director
  • 19.5. Clariness
    • 19.5.1. Company Snapshot
    • 19.5.2. Interview Transcript: Stefan Mayer-Eggersmann, Chief Commercial Officer
  • 19.6. Continuum Clinical
    • 19.6.1. Company Snapshot
    • 19.6.2. Interview Transcript: Ken Shore, Chief Commercial Officer
  • 19.7. nRollmed
    • 19.7.1. Company Snapshot
    • 19.7.2. Interview Transcript: Hagit Nof, Chief Operation Officer and Business Development Officer
  • 19.8. Seeker Health
    • 19.8.1. Company Snapshot
    • 19.8.2. Interview Transcript: Paul Ivsin, Ex Managing Director
  • 19.9. EVERSANA
    • 19.9.1. Company Snapshot
    • 19.9.2. Interview Transcript: Kasturi Lakhe, Inside Sales Specialist

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100391

LIST OF TABLES

  • Table 3.1 Key Characteristics of Clinical Trial Phases
  • Table 4.1 Traditional and Emerging Patient Outreach Methods
  • Table 5.1 List of Patient Recruitment and Retention Service Providers
  • Table 5.2 Patient Recruitment and Retention Service Providers: Information on Patient Outreach Methods
  • Table 5.3 Patient Recruitment and Retention Service Providers: Information on Type of Patient Recruitment Service(s) Offered
  • Table 5.4 Patient Recruitment and Retention Service Providers: Information on Patient Retention Method(s) Used and Geographical Reach
  • Table 5.5 Patient Recruitment and Retention Service Providers: Information on Therapeutic Expertise
  • Table 5.6 Patient Recruitment and Retention Service Providers: Information on Payment Model, Patient Recruitment Technology / Platform and Regulatory Compliance Status
  • Table 7.1 Leading Patient Recruitment Service Providers in North America
  • Table 7.2 BBK Worldwide: Company Overview
  • Table 7.3 BBK Worldwide: Patient Recruitment and Retention Services Portfolio
  • Table 7.4 BBK Worldwide: Recent Developments and Future Outlook
  • Table 7.5 Continuum Clinical: Company Overview
  • Table 7.6 Continuum Clinical: Patient Recruitment and Retention Services Portfolio
  • Table 7.7 Continuum Clinical: Recent Developments and Future Outlook
  • Table 7.8 IQVIA: Company Overview
  • Table 7.9 IQVIA: Patient Recruitment and Retention Services Portfolio
  • Table 7.10 IQVIA: Recent Developments and Future Outlook
  • Table 7.11 United BioSource: Company Overview
  • Table 7.12 United BioSource: Patient Recruitment and Retention Services Portfolio
  • Table 7.13 United BioSource: Recent Developments and Future Outlook
  • Table 7.14 WCG ThreeWire: Company Overview
  • Table 7.15 WCG ThreeWire: Patient Recruitment and Retention Services Portfolio
  • Table 7.16 WCG ThreeWire: Recent Developments and Future Outlook
  • Table 8.1 Leading Patient Recruitment Service Providers in Europe
  • Table 8.2 Clariness: Company Overview
  • Table 8.3 Clariness: Patient Recruitment and Retention Services Portfolio
  • Table 8.4 Clariness: Recent Developments and Future Outlook
  • Table 8.5 Ignite Data: Company Overview
  • Table 8.6 Ignite Data: Patient Recruitment and Retention Services Portfolio
  • Table 8.7 Ignite Data: Recent Developments and Future Outlook
  • Table 8.8 Innovative Trials: Company Overview
  • Table 8.9 Innovative Trials: Patient Recruitment and Retention Services Portfolio
  • Table 8.10 Innovative Trials: Recent Developments and Future Outlook
  • Table 8.11 One Research: Company Overview
  • Table 8.12 One Research: Patient Recruitment and Retention Services Portfolio
  • Table 8.13 Orphan Reach: Company Overview
  • Table 8.14 Orphan Reach: Patient Recruitment and Retention Services Portfolio
  • Table 8.15 Orphan Reach: Recent Developments and Future Outlook
  • Table 9.1 Leading Patient Recruitment Service Providers in Asia Pacific and Rest of the World
  • Table 9.2 3H Medi Solution: Company Overview
  • Table 9.3 3H Medi Solution: Patient Recruitment and Retention Services Portfolio
  • Table 9.4 3H Medi Solution: Recent Developments and Future Outlook
  • Table 9.5 Buzzreach: Company Overview
  • Table 9.6 Buzzreach: Patient Recruitment and Retention Services Portfolio
  • Table 9.7 Buzzreach: Recent Developments and Future Outlook
  • Table 9.8 Current Medical Information Center: Company Overview
  • Table 9.9 Current Medical Information Center: Patient Recruitment and Retention Services Portfolio
  • Table 9.10 Current Medical Information Center: Recent Developments and Future Outlook
  • Table 9.11 nRollmed: Company Overview
  • Table 9.12 nRollmed: Patient Recruitment and Retention Services PortfolioF
  • Table 9.13 Trialfacts: Company Overview
  • Table 9.14 Trialfacts: Patient Recruitment and Retention Services Portfolio
  • Table 9.15 Trialfacts: Recent Developments and Future Outlook
  • Table 10.1 Patient Recruitment and Retention Services: List of Partnerships and Collaborations, 2013-2022
  • Table 14.1 Patient Recruitment Service Providers: List of Trials Focused on Personalized Medicines and Rare Diseases
  • Table 15.1 Global Demand for Clinical Trial Participants: Average Number of Patients Enrolled by Trial Phase
  • Table 19.1 TrialWire: Company Snapshot
  • Table 19.2 Innovative Trials: Company Snapshot
  • Table 19.3 Link2Trials: Company Snapshot
  • Table 19.4 Clariness: Company Snapshot
  • Table 19.5 Continuum Clinical: Company Snapshot
  • Table 19.6 nRollmed: Company Snapshot
  • Table 19.7 Seeker Health: Company Snapshot
  • Table 19.8 EVERSANA: Company Snapshot
  • Table 20.1 Factors Contributing to Clinical Trial Cost
  • Table 20.2 Patient Recruitment and Retention Service Providers: Distribution by Year of Establishment
  • Table 20.3 Patient Recruitment and Retention Service Providers: Distribution by Company Size
  • Table 20.4 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters (Region-wise)
  • Table 20.5 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters (Country-wise)
  • Table 20.6 Patient Recruitment and Retention Service Providers: Distribution by Company Size and Location of Headquarters
  • Table 20.7 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment and Retention Services Offered
  • Table 20.8 Patient Recruitment and Retention Service Providers: Distribution by Type of Patient Outreach Method(s)
  • Table 20.9 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Outreach Method(s)
  • Table 20.10 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment Associated Service(s) Offered
  • Table 20.11 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Recruitment Associated Service(s) Offered
  • Table 20.12 Patient Recruitment and Retention Service Providers: Distribution by Patient Retention Method(s) Used
  • Table 20.13 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Retention Method(s) Used
  • Table 20.14 Patient Recruitment and Retention Service Providers: Distribution by Geographical Reach
  • Table 20.15 Patient Recruitment and Retention Service Providers: Distribution by Therapeutic Expertise
  • Table 20.16 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 20.17 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 20.18 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 20.19 Partnerships and Collaborations: Distribution by Focus Area
  • Table 20.20 Partnerships and Collaborations: Distribution by Year of Partnership and Focus Area
  • Table 20.21 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 20.22 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 20.23 Most Active Players: Distribution by Number of Partnerships
  • Table 20.24 Partnerships and Collaborations: Intracontinental and Intercontinental Distribution
  • Table 20.25 Partnerships and Collaborations: International and Local Distribution
  • Table 20.26 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
  • Table 20.27 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 20.28 Global Demand for Clinical Trial Participants: Distribution by Enrolled Patient Population (Million Patients)
  • Table 20.29 Global Demand for Clinical Trial Participants: Distribution by Trial Phase (Million Patients)
  • Table 20.30 Global Demand for Clinical Trial Participants: Distribution by Therapeutic Area (Million Patients)
  • Table 20.31 Global Demand for Clinical Trial Participants: Distribution by Geography (Million Patients)
  • Table 20.32 Global Patient Recruitment Services Market, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.33 Patient Recruitment Services Market: Distribution by Patient Recruitment Steps, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.34 Patient Recruitment Services Market: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.35 Patient Recruitment Services Market: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.36 Patient Recruitment Services Market: Distribution by Geography, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.37 Patient Recruitment Services Market, 2022 and 2035: Market Attractiveness Distribution by Country
  • Table 20.38 Patient Recruitment Services Market in North America, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.39 Patient Recruitment Services Market in the US: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.40 Patient Recruitment Services Market in the US: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.42 Patient Recruitment Services Market in Canada: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.43 Patient Recruitment Services Market in Canada: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.44 Patient Recruitment Services Market in Europe, 2022-2035 (USD Billion)
  • Table 20.45 Patient Recruitment Services Market in Germany: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.46 Patient Recruitment Services Market in Germany: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.47 Patient Recruitment Services Market in France: Distribution by Trial Phase,2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.48 Patient Recruitment Services Market in France: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.49 Patient Recruitment Services Market in the UK: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.50 Patient Recruitment Services Market in the UK: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.51 Patient Recruitment Services Market in Italy: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.52 Patient Recruitment Services Market in Italy: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.53 Patient Recruitment Services Market in Spain: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.54 Patient Recruitment Services Market in Spain: Distribution by Therapeutic Area, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.55 Patient Recruitment Services Market in Rest of Europe: Distribution by Trial Phase, 2022-2035, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.56 Patient Recruitment Services Market in Rest of Europe: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.57 Patient Recruitment Services Market in Asia Pacific, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.58 Patient Recruitment Services Market in Japan: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.59 Patient Recruitment Services Market in Japan: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.60 Patient Recruitment Services Market in South Korea: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.61 Patient Recruitment Services Market in South Korea, 2022-2035: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.62 Patient Recruitment Services Market in Australia: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.63 Patient Recruitment Services Market in Australia: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.64 Patient Recruitment Services Market in China: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.65 Patient Recruitment Services Market in China: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.66 Patient Recruitment Services Market in India: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.67 Patient Recruitment Services Market in India: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.68 Patient Recruitment Services Market in Latin America, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.69 Patient Recruitment Services Market in Latin America: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.70 Patient Recruitment Services Market in Latin America: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.71 Patient Recruitment Services Market in Middle East and North Africa, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.72 Patient Recruitment Services Market in Middle East and North Africa: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.73 Patient Recruitment Services Market in Middle East and North Africa: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.74 Patient Recruitment Services Market in Rest of the World, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.75 Patient Recruitment Services Market in Rest of the World: Distribution by Trial Phase, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 20.76 Patient Recruitment Services Market in Rest of the World, 2022-2035: Distribution by Therapeutic Area, 2022-2035: Conservative, Base and Optimistic Scenario (USD Billion)

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Partnership and Collaborations
  • Figure 2.3 Executive Summary: Analysis of Demand for Clinical Trial Participants
  • Figure 2.4 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 3.1 Factors Contributing to Clinical Trial Cost
  • Figure 3.2 Patient Recruitment Process
  • Figure 3.3 Factors Influencing Participation in Clinical Trials
  • Figure 3.4 Reasons for Patient Dropouts from Clinical Studies
  • Figure 4.1 Patient Outreach: Advantages and Limitations of Traditional Methods
  • Figure 4.2 Patient Outreach: Advantages and Limitations of Social Media
  • Figure 5.1 Patient Recruitment and Retention Service Providers: Distribution by Year of Establishment
  • Figure 5.2 Patient Recruitment and Retention Service Providers: Distribution by Company Size
  • Figure 5.3 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters (Region-wise)
  • Figure 5.4 Patient Recruitment and Retention Service Providers: Distribution by Location of Headquarters (Country-wise)
  • Figure 5.5 Patient Recruitment and Retention Service Providers: Distribution by Company Size and Location of Headquarters
  • Figure 5.6 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment and Retention Services Offered
  • Figure 5.7 Patient Recruitment and Retention Service Providers: Distribution by Type of Patient Outreach Method(s)
  • Figure 5.8 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Outreach Method(s)
  • Figure 5.9 Patient Recruitment and Retention Service Providers: Distribution by Patient Recruitment Associated Service(s) Offered
  • Figure 5.10 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Recruitment Associated Service(s) Offered
  • Figure 5.11 Patient Recruitment and Retention Service Providers: Distribution by Patient Retention Method(s) Used
  • Figure 5.12 Patient Recruitment and Retention Service Providers: Distribution by Number of Patient Retention Method(s) Used
  • Figure 5.13 Patient Recruitment and Retention Service Providers: Distribution by Geographical Reach
  • Figure 5.14 Patient Recruitment and Retention Service Providers: Distribution by Therapeutic Expertise
  • Figure 6.1 Company Competitiveness Analysis: Small Companies
  • Figure 6.2 Company Competitiveness Analysis: Mid-sized Companies
  • Figure 6.3 Company Competitiveness Analysis: Large and Very Large Companies
  • Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 10.4 Partnerships and Collaborations: Distribution by Focus Area
  • Figure 10.5 Partnerships and Collaborations: Distribution by Year of Partnership and Focus Area
  • Figure 10.6 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 10.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 10.9 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
  • Figure 10.10 Partnerships and Collaborations: International and Local Deals
  • Figure 11.1 Patient Recruitment Services Market: Recent Trends
  • Figure 12.1 Patient Recruitment Services Market: Future Growth Opportunities
  • Figure 12.2 Global Clinical Trials Registered, 2000-2022
  • Figure 13.1 Patient Recruitment: Regulatory Pathway
  • Figure 13.2 Patient Recruitment: Regulatory Guidelines
  • Figure 14.1 Key Challenges in Patient Enrolment in Trials Focused on Personalized Medicines
  • Figure 14.2 Key Challenges in Patient Enrolment in Trials Focused on Rare Diseases
  • Figure 14.3 Specialized Patient Outreach Methods
  • Figure 15.1 Analysis of Demand for Clinical Trial Participants: Scope and Methodology
  • Figure 15.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
  • Figure 15.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 15.4 Global Demand for Clinical Trial Participants: Distribution by Enrolled Patient Population (Million Patients)
  • Figure 15.5 Global Demand for Clinical Trial Participants: Distribution by Trial Phase (Million Patients)
  • Figure 15.6 Global Demand for Clinical Trial Participants: Distribution by Therapeutic Area (Million Patients)
  • Figure 15.7 Global Demand for Clinical Trial Participants: Distribution by Geography (Million Patients)
  • Figure 16.1 Movement of Patients in Patient Recruitment Process
  • Figure 16.2 Global Patient Recruitment Services Market, 2022-2035 (USD Billion)
  • Figure 16.3 Patient Recruitment Services Market: Distribution by Patient Recruitment Steps, 2022-2035 (USD Billion)
  • Figure 16.4 Patient Recruitment Services Market: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.5 Patient Recruitment Services Market: Distribution by Therapeutic Area, 2022- 2035 (USD Billion)
  • Figure 16.6 Patient Recruitment Services Market: Distribution by Geography, 2022-2035 (USD Billion)
  • Figure 16.7 Patient Recruitment Services Market, 2022 and 2035: Market Attractiveness Distribution by Country
  • Figure 16.8 Patient Recruitment Services Market in North America, 2022-2035 (USD Billion)
  • Figure 16.9 Patient Recruitment Services Market in the US: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.10 Patient Recruitment Services Market in the US: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.11 Patient Recruitment Services Market in Canada: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.12 Patient Recruitment Services Market in Canada: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.13 Patient Recruitment Services Market in Europe, 2022-2035 (USD Billion)
  • Figure 16.14 Patient Recruitment Services Market in Germany: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.15 Patient Recruitment Services Market in Germany: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.16 Patient Recruitment Services Market in France: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.17 Patient Recruitment Services Market in France: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.18 Patient Recruitment Services Market in the UK: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.19 Patient Recruitment Services Market in the UK: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.20 Patient Recruitment Services Market in Italy: Distribution by Trial Phase, 2022- 2035 (USD Billion)
  • Figure 16.21 Patient Recruitment Services Market in Italy: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.22 Patient Recruitment Services Market in Spain: Distribution by Trial Phase, 2022- 2035 (USD Billion)
  • Figure 16.23 Patient Recruitment Services Market in Spain: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.24 Patient Recruitment Services Market in Rest of Europe: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.25 Patient Recruitment Services Market in Rest of Europe: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.26 Patient Recruitment Services Market in Asia Pacific, 2022-2035 (USD Billion)
  • Figure 16.27 Patient Recruitment Services Market in Japan: Distribution by Trial Phase, 2022- 2035 (USD Billion)
  • Figure 16.28 Patient Recruitment Services Market in Japan: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.29 Patient Recruitment Services Market in South Korea: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.30 Patient Recruitment Services Market in South Korea, 2022-2035: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.31 Patient Recruitment Services Market in Australia: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.32 Patient Recruitment Services Market in Australia: Distribution by Therapeutic Area (USD Billion)
  • Figure 16.33 Patient Recruitment Services Market in China: Distribution by Trial Phase, 2022- 2035 (USD Billion)
  • Figure 16.34 Patient Recruitment Services Market in China: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.35 Patient Recruitment Services Market in India: Distribution by Trial Phase, 2022- 2035 (USD Billion)
  • Figure 16.36 Patient Recruitment Services Market in India: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.37 Patient Recruitment Services Market in Latin America, 2022-2035 (USD Billion)
  • Figure 16.38 Patient Recruitment Services Market in Latin America: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.39 Patient Recruitment Services Market in Latin America: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.40 Patient Recruitment Services Market in Middle East and North Africa, 2022-2035 (USD Billion)
  • Figure 16.41 Patient Recruitment Services Market in Middle East and North Africa: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.42 Patient Recruitment Services Market in Middle East and North Africa: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 16.43 Patient Recruitment Services Market in Rest of the World, 2022-2035 (USD Billion)
  • Figure 16.44 Patient Recruitment Services Market in Rest of the World: Distribution by Trial Phase, 2022-2035 (USD Billion)
  • Figure 16.45 Patient Recruitment Services Market in Rest of the World, 2022-2035: Distribution by Therapeutic Area, 2022-2035 (USD Billion)
  • Figure 18.1 Concluding Remarks: Overall Market Landscape
  • Figure 18.2 Concluding Remarks: Company Competitiveness Analysis
  • Figure 18.3 Concluding Remarks: Partnership and Collaborations
  • Figure 18.4 Concluding Remarks: Analysis of Demand for Clinical Trial Participants
  • Figure 18.5 Concluding Remarks: Market Sizing and Opportunity Analysis
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!